Lataa...
ESR1 Mutations in Breast Cancer
The acquisition of ligand-independent ESR1 mutations during aromatase inhibitor (AI) therapy in metastatic estrogen receptor (ER)-positive breast cancer is a common mechanism of hormonal therapy resistance. Preclinical and clinical studies have demonstrated that ESR1 mutations can pre-exist in prima...
Tallennettuna:
| Julkaisussa: | Cancer |
|---|---|
| Päätekijät: | , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6788940/ https://ncbi.nlm.nih.gov/pubmed/31318440 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32345 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|